...
首页> 外文期刊>Oncogenesis. >Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines
【24h】

Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines

机译:多种受体酪氨酸激酶促进转移性人骨肉瘤细胞株的体外表型

获取原文
           

摘要

The survival rate for osteosarcoma patients with localized disease is 70% and only 25% for patients with metastases. Therefore, novel therapeutic and prognostic tools are needed. In this study, extensive screening and validation strategies identified Axl, EphB2, FGFR2, IGF-1R and Ret as specific receptor tyrosine kinases (RTKs) that are activated and promote the in vitro phenotype of two genetically different metastatic osteosarcoma cell lines. Initial phosphoproteomic screening identified twelve RTKs that were phosphorylated in 143B and/or LM7 metastatic human osteosarcoma cells. A small interfering RNA (siRNA) screen demonstrated that siRNA pools targeting ten of the twelve RTKS inhibited the in vitro phenotype of one or both cell lines. To validate the results, we individually tested the four siRNA duplexes that comprised each of the effective siRNA pools from the initial screen. The pattern of phenotype inhibition replicated the pattern of mRNA knockdown by the individual duplexes for seven of the ten RTKs, indicating the effects are consistent with on-target silencing. Five of those seven RTKs were further validated using independent approaches including neutralizing antibodies (IGF-1R), antisense-mediated knockdown (EphB2, FGFR2, and Ret) or small molecule inhibitors (Axl), indicating that those specific RTKs promote the in vitro behavior of metastatic osteosarcoma cell lines and are potential therapeutic targets for osteosarcoma. Immunohistochemistry demonstrated that Axl is frequently activated in osteosarcoma patient biopsy samples, further supporting our screening and validation methods to identify RTKs that may be valuable targets for novel therapies for osteosarcoma patients.. ? 2012 Macmillan Publishers Limited
机译:局部疾病的骨肉瘤患者的生存率为70%,而转移灶的患者仅为25%。因此,需要新颖的治疗和预后工具。在这项研究中,广泛的筛选和验证策略将Axl,EphB2,FGFR2,IGF-1R和Ret识别为特异性受体酪氨酸激酶(RTK),这些酪氨酸激酶被激活并促进两种遗传上不同的转移性骨肉瘤细胞系的体外表型。最初的蛋白质组学筛选确定了在143B和/或LM7转移性人骨肉瘤细胞中被磷酸化的十二种RTK。一个小的干扰RNA(siRNA)筛选表明,靶向12种RTKS中的10种的siRNA池抑制了一种或两种细胞系的体外表型。为了验证结果,我们从初始筛选中分别测试了包含每个有效siRNA库的四个siRNA双链体。表型抑制的模式复制了十个RTK中的七个RTK的单个双链体敲低mRNA的模式,表明这种作用与靶向沉默相一致。使用独立方法进一步验证了这七个RTK中的五个,包括中和抗体(IGF-1R),反义介导的敲低(EphB2,FGFR2和Ret)或小分子抑制剂(Axl),表明这些特定的RTK促进了体外行为转移性骨肉瘤细胞系的表达,是骨肉瘤的潜在治疗靶标。免疫组织化学表明,Axl在骨肉瘤患者的活检样本中经常被激活,这进一步支持了我们的筛选和验证方法,以鉴定可能是骨肉瘤患者新疗法有价值的靶标的RTK。 2012 Macmillan Publishers Limited

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号